Literature DB >> 12213567

Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling.

Jacques Pouysségur1, Véronique Volmat, Philippe Lenormand.   

Abstract

Extracellular signals transduced via receptor tyrosine kinases, G-protein-coupled receptors or integrins activate Ras, a key switch in cellular signalling. Although Ras can activate multiple downstream effectors (PI3K, Ral em leader ) one of the major activated pathway is a conserved sequential protein kinase cascade referred to as the mitogen activated protein (MAP) kinase module: Raf>MEK>ERK. The fidelity of signalling among protein kinases and the spatio-temporal activation are certainly key determinants for generating precise biological responses. The fidelity is ensured by scaffold proteins, a sort of protein kinase "insulators" and/or specific docking sites among the members of the signalling cascade. These docking sites are found in upstream and downstream regulators and MAPK substrates [Nat Cell Biol 2 2000 110]. The duration and the intensity of the response are in part controlled by the compartmentalisation of the signalling molecules. Growth factors promote nuclear accumulation and persistent activation of ERK (p42/p44 MAP kinases) during the entire G1 period with an extinction during S-phase. These features are exquisitely well controlled by (i) the temporal induction of the MAP kinase phosphatases, MKP1-3, and (ii) the compartmentalisation of the signalling molecules. We have shown that MKP1-2 induction is strictly controlled by the activation of the MAP kinase module providing evidence for an autoregulatory mechanism. This negative regulatory loop was further enhanced by the capacity of ERK to phosphorylate MKP1 and 2. This action reduced the degradation rate of these MKPs through the ubiquitin-proteasomal system [Science 286 1999 2514]. Whereas the two upstream kinases of the module, Raf and MEK remained cytoplasmic, ERK anchored to MEK in the cytoplasm of resting cells, rapidly translocated to the nucleus upon mitogenic stimulation. This process was rapid, reversible, and controlled by the strict activation of the MAPK cascade. Prevention of this nuclear translocation, by overexpression of a cytoplasmic ERK-docking molecule (inactive MKP3) prevented growth factor-stimulated DNA replication [EMBO J 18 1999 664]. Following long term stimulation, ERK progressively accumulated in the nucleus in an inactive form. This nuclear retention relied on the neosynthesis of short-lived nuclear anchoring proteins. Nuclear inactivation and sequestration was likely to be controlled by MAP kinase phosphatases 1 and 2. Therefore we propose that the nucleus represents a site for ERK action, sequestration and signal termination [J Cell Sci 114 2001 3433]. In addition, with the generation of mice invalidated for each of the ERK isoforms, we will illustrate that besides controlling cell proliferation the ERK cascade also controls cell differentiation and cell behaviour [Science 286 1999 1374].

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213567     DOI: 10.1016/s0006-2952(02)01135-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  114 in total

Review 1.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

2.  The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells.

Authors:  Robert L Kortum; Robert E Lewis
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

Review 3.  Oxidative neuronal injury. The dark side of ERK1/2.

Authors:  Charleen T Chu; David J Levinthal; Scott M Kulich; Elisabeth M Chalovich; Donald B DeFranco
Journal:  Eur J Biochem       Date:  2004-06

4.  Hippocampal Mek/Erk signaling mediates extinction of contextual freezing behavior.

Authors:  Andre Fischer; Marko Radulovic; Christina Schrick; Farahnaz Sananbenesi; Jasminka Godovac-Zimmermann; Jelena Radulovic
Journal:  Neurobiol Learn Mem       Date:  2006-09-18       Impact factor: 2.877

5.  Distinct requirements for the Sprouty domain for functional activity of Spred proteins.

Authors:  James A J King; Andrew F L Straffon; Giovanna M D'Abaco; Carole L C Poon; Stacey T T I; Craig M Smith; Michael Buchert; Niall M Corcoran; Nathan E Hall; Bernard A Callus; Boris Sarcevic; Daniel Martin; Peter Lock; Christopher M Hovens
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

6.  Mechanical compression of articular cartilage induces chondrocyte proliferation and inhibits proteoglycan synthesis by activation of the ERK pathway: implications for tissue engineering and regenerative medicine.

Authors:  James A Ryan; Eric A Eisner; Grayson DuRaine; Zongbing You; A Hari Reddi
Journal:  J Tissue Eng Regen Med       Date:  2009-02       Impact factor: 3.963

7.  Blockade of ERK1/2 by U0126 alleviates uric acid-induced EMT and tubular cell injury in rats with hyperuricemic nephropathy.

Authors:  Min Tao; Yingfeng Shi; Lunxian Tang; Yi Wang; Lu Fang; Wei Jiang; Tao Lin; Andong Qiu; Shougang Zhuang; Na Liu
Journal:  Am J Physiol Renal Physiol       Date:  2019-01-16

8.  Regulatory mechanisms of fear extinction and depression-like behavior.

Authors:  Natalie C Tronson; Christina Schrick; Andre Fischer; Farahnaz Sananbenesi; Gilles Pagès; Jacques Pouysségur; Jelena Radulovic
Journal:  Neuropsychopharmacology       Date:  2007-08-22       Impact factor: 7.853

9.  MAT2B-GIT1 interplay activates MEK1/ERK 1 and 2 to induce growth in human liver and colon cancer.

Authors:  Hui Peng; Lily Dara; Tony W H Li; Yuhua Zheng; Heping Yang; Maria Lauda Tomasi; Ivan Tomasi; Pasquale Giordano; Jose M Mato; Shelly C Lu
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

10.  Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity.

Authors:  Philippe P Roux; Stephanie A Richards; John Blenis
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.